Background: Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody which effectively depletes B cells and is used for treating rheumatoid arthritis (RA). Objectives: To assess the efficacy and safety of RTX and to evaluate the predictors of response to RTX in the treatment of Iraqi patients with active RA.
INTRODUCTION R
A is a chronic, systemic inflammatory disease that affects the synovium, leading to synovial inflammation and proliferation, loss of articular cartilage, and erosion of juxta-articular bone. The natural history of the disease is one of progressive joint damage and deformity and, in a few people, the development of extra-ethnic groups as it may drop to 0.3% in the Chinese [3] and increase to 5% in Pima Indians of Arizona [4] . Definite RA was observed in 1% of population samples in Iraq [5] . The pathogenesis RA remains vague and more than 30 loci conferring risk genetics for RA have been identified. The most potent genetic risk factor is HLA DR1, HLA DR4. The shared epitope (SE) is associated with the production of specific antibodies, especially anti-cyclic citrullinated peptide (CCP) antibodies [1] . The highest incidence of RA in women occurs after menopause when the level of sex hormones decreases and pregnancy is often associated with disease remission. Bacterial and viral components were isolated from the synovial fluid of the affected joints by polymerase chain reaction technique. EBV and parvovirus B19 are most infections associated with RA. Smoking is significantly enhancing the risk of developing RA, this association has been strong in men and in those with RF and ACPA positive disease [6] . The multiple criteria used for the diagnosis of RA depend on clinical history, physical examination, and Lab. tests. These criteria are not for diagnostic purposes, but they are mainly used in Classifying patients for clinical research [7] . There is the 1987 American College of Rheumatology (ACR) Criteria for RA and the new classification system which has been proposed by ACR and European League against Rheumatism (EULAR) and useful in the diagnosis of early disease [8] .
Rheumatoid factor (RF) is an autoantibody directed against the Fc portion of IgG. RF is positive in about 50% of cases at presentation and 85% of cases positive in the first 6 months after diagnosis and is about 70% sensitive and 80% specific for RA. Anti-cyclic citrullinated peptide antibodies are key autoantibody in RA. It has a sensitivity of up to 80% and a specificity of 98% for RA [2] .
Treatment needs teamwork for patient care between physicians, nurses, physiotherapists, occupational therapists, social workers, and surgeons. The treatment aims:
1. To decrease the inflammation and damage. 2. To decrease long term disability. 3. To prevent extra-articular morbidity and mortality [9] .
There are four classes of medications used in RA: 1. All patients should be received analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs). Sideeffects can be avoided by concomitant use of a gastroprotectant. 2. Earlier use of disease-modifying anti-rheumatic drug (DMARD) therapy to optimally inhibit synovitis and reduce disease activity and slowing joint destruction [10] . 3. Corticosteroids are potent anti-inflammatory drugs and long-term use is associated with significant morbidities, such as osteoporosis and vertebral fracture. Its use as bridge the time until DMARDs are effective [11] . 4. Biologic agents, the advent of biologics has brought a revolutionary change in RA care.
The biological drugs act by one of the following mechanisms:
• Cytokine modulation.
• Targeting T cells.
• Targeting B cells.
The B lymphocyte depletion as a technique to therapy has been established in RA patients seropositive for RF and/or anti-CCP antibodies using the anti-CD20 chimeric monoclonal antibody, RTX. It is successfully depleted B cells for up to 6−12 months, which is associated with improvement in RA disease activity and re-treatment when the B cell compartment repopulates [10] . RTX is used for resistant cases and for special cases of RA. It is standard as a second line after anti-TNF failure, for the treatment of severe RA. Use 1000 mg intravenous (IV) infusion, repeated after 2 weeks (2 infusions separated by 2 weeks (one course). Repeat the course after 24 weeks, according to clinical examination Use acetaminophen and antihistamine before rituximab dose 375 mg/m 2 IV per Week for 4 weeks. Use methylprednisolone 1 g IV/day for 1−3 days, oral prednisone 1 mg/kg/day; maximum 80 mg/day and taper according to clinical assessment [12] .
Common side effects of RTX which occurred in 10% of patients like abdominal pain, systemic hypertension, headache, and dizziness. While others like hypercalcemia, spontaneous bone fracture, and coagulation disorders occurred in less than 1% [13] . RTX has shown to be safe, although the lake of longterm efficacy and safety data limit its use. More studies are needed [14] .
The aims of this study were: 1. To assess the efficacy and safety of RTX in Iraqi patients with active RA. 2. To assess the predictors of response to RTX in treatment of patients with active RA.
MATERIALS AND METHODS
This was an open-labeled single group longitudinal study that was conducted over 13 months period. The study was conducted on Iraqi patients with RA who visited the Rheumatology Ward in Baghdad Teaching Hospital from June 2015 to July 2016.
Characters of patients

The patient should meet the 1987 American College of
Rheumatology criteria for the classification of RA. 2. The CDAI should be equal to or greater than 13 (moderately to severely active disease). 3. The age of more than 16. 4. Patients do not have other CTD overlaps with RA During the study period, 65 patients with RA were identified and enrolled in the study. All of them successfully completed the study.
Methods
All the included patients were given RTX 1g (2 vials 500mg) IV infusion for 2 cycles (6 months apart), each cycle has 2 doses (2 weeks apart). Methylprednisolone 100 mg infusion in 250 cc N/S, all ermine ampoule 10 mg and paracetamol tablet 1gm half an hour before the RTX. For each patient, baseline data were collected during the first visit and after 2 weeks and all the participants were seen after 6 months and after 2 weeks (4 visits). During these subsequent visits, further data were taken. The data were collected by the researcher and registered in a patient information sheet that was designed by the researcher and revised by the supervisor.
The collected data include 1. Demographic data of patients regarding their age and sex as well as smoking status. These data were collected at the first visit. 2. Medical data, including the disease duration, previous and current RA medications (MTX and biologic). These data were also collected during the first visit. 3. Lab data which include RF, ACPA and Hemoglobin level( Hb), white blood cell (WBC) count. http://doi.org/10.33091/AMJ.0401512019 
Statistical analysis
The data of the 65 patients in this study were entered into and analyzed by the statistical package for social science (SPSS) software version 17. Descriptive statistics were presented as mean, standard deviation, frequencies, and percentage. The efficacy of RTX was tested by comparing the mean difference of CDAI and the mean difference of ESR between the baseline and the last visit using a paired t-test. The efficacy of RTX was also assessed by comparing the change in the functional class in RA patients with time. This was tested using the Chi-square test (χ 2 ).
Student's t-test was used to assess the effect of patient characteristics (as predictors) on the response to treatment. The percentage of mean difference in CDAI between baseline and the last visit was used as the dependent variable to assess the difference between these factors and the response to treatment. The correlation test is used to assess the relationship between patient characteristics [age, BMI, disease duration] and percentage of mean difference in CDAI between baseline and last visit [as the response to treatment]. A level of significance (P value) of 0.05 was considered significant.
RESULTS
There were 65 patients enrolled in this longitudinal study with a mean age of (49.5) years and a range of (27−70) years. Female patients were 58 (89.2%) and males were 7(10.8%).
Smokers were 16 patients (24.6%), RF was positive in 41 patients (82%) ( data available in 50 patients only), ACPA was positive in 50 patients (80.6%) (data obtained for 62 patients), 49 patients (75.3%) were taking MTX., 29 patients took TNFblocker before RTX (4 developed S/E and 25 failed to respond), while 36 started on RTX ( 9 were PPD positive and the reminder started on RTX because none available TNFblocker for about 4 months during the study) Table 1 .
The efficacy of RTX was tested by comparing mean difference of CDAI between the first visit (37.54+6.42) and the last visit (18.98+10.14) by using Paired t-test, which revealed a highly significant difference (p<0.005). As shown in Figure 1 . In Figure 2 we used the Chi-square test ( χ 2 ) to compare the changes in the functional class of RA patients during the follow-up period. There was a significant improvement in functional class with advancing treatment time. At baseline, 2 patients (3%) were FC I, 11 patients (17%) were class II, 26 patients (40%) were both class III and IV After sixth month of follow up the figures were changed to 26 patients (40%) in class I and only 3 patient (5%) in class IV which is significant (P= 0.0001).
To assess the effect of patients' characteristics on response to treatment, students t-test was conducted using 6 variables as predictors, These include the gender, smoking status and the concomitant use of methotrexate, previous biological use, the presence of RF, and the presence of ACPA. And the corre- lation test was conducted using 3 variables, age, disease duration, and BMI The percentage of mean difference of CDAI between the baseline and the last visit was used as a dependent variable in the student's t-test model. The analysis showed that smoking has a significant effect on response to treatment with the non -smoker being more respondent to treatment than the smoker group (P-value = 0.005 ). From the statistical point of view, there was a great decrease in CDAI in RF-positive group (−53.6%) compared for the RF-negative group (−41.2%), it was not proved statistically probably because of the big difference in the No. of these groups (41 vs 9). The other variables (including age, gender, disease duration, presence of ACPA, MTX use, previous biological use and BMI) had no significant effect on response to treatment (p>0.05). The finding is shown in Table 2 . The most common side effects reported in this study was infusion reaction(sore throat, flushing, nasal congestion) documented in 17 patients (26.15%). Other side effects are shown in Table 3 . No one develops hypotension, no one develops anaphylaxis.
DISCUSSION
In patients with RA, evaluation of joint synovitis and its response to treatment is based on clinical findings and acute phase reactants. Many DMARDs and biological agents are available for the treatment of RA. Because biological agents are costly, finding the characteristics of the groups of patients who respond more to these agents is of great interest [14] [15] [16] RTX is one of the biological agents used for resistant and special cases of moderately to severely active RA. Clinical, and Lab. factors have been associated with early response (6ms) to RTX therapy in RA [15, 16] .
This study is the first observational study about the efficacy and safety of RTX conducted on RA patients in Iraq. Data analysis showed significant improvement in disease activity CDAI (p= 0.005), functional class (p=0.001) and ESR (p<0.005) with RTX use over a period of 6 months. Richter A. et al (2014) proved in his study in Germany that RTX treatment led to improvements in disease activity and functional state that were sustained over multiple courses [17] . Ronald F. et al (2015) wrote the final report of the RA Global Clinical Trial Program over 11 years and he confirmed that RTX has a consistent safety and efficacy profile over time and multiple courses up to 11 years of observation [18] .
In this study, we evaluated the correlation between nine patient characteristics (age, gender, diseases duration, the presence of RF, the presence of ACPA, previous anti-TNF use, smoking status, the concomitant use of methotrexate and BMI) and the response to RTX. There was a significant inverse correlation between smoking and a reduction in disease activity (CDAI) (P=0.005). This was proved by Abdul Khan1. [19] in his study: smoking, RF status and responses to RTX, non-smokers have a very high response rate to RTX irrespective of their RF/ACPA status, in comparison, the smokers only achieve the response rate of 50
This study showed that there was more response in the RFpositive group from the RF-negative group. The RF positivity also was significant both by Luca Q. et al study (p=0.0001) [16] , Lopez-Olivo [20] , Isaacs JD [21] and Wendler J 2014 [22] . This study found (as in Wendler J.study) that the age did not affect RTX efficacy, while Luca Q. et al found that the older the age, the more response to RTX (p=0.01). We found MTX use was not related to the efficacy of RTX, this also proved by Richter A in German biologics register (2014) [17] . This study showed no difference between patients who started on RTX (n=36) and those who switched to RTX after use of TNF-blocker (n=29), while the previous failure to TNF blockers was positively related to RTX efficacy as proved by Lopez-Olivo [20] .
This study and Wendler J. [22] did not prove that seropositivity for ACPA was associated with a superior clinical response to RTX, while Lopez-Olivo [20] did, and Jeremie S. in a Multicenter, Open-Label Study showed ACPA may be used http://doi.org/10.33091/AMJ.0401512019 to predict the clinical response to a single course of RTX in patients with refractory RA [23] . In this study we did not found a relation between the gender, disease duration, and body mass index and response to treatment. The reported adverse effects of RTX in this study were in the form of descriptive statistics to give an idea about the most common side effects experienced by the patients. Unfortunately, the inferential statistic regarding drug safety was not possible due to the lack of a control group.
The most common side effect which occurs during RTX infusion is transfusion reaction in form of sore throat and nasal congestion with flushing( occur in 17 (26.17%) patients), although this was transient and was relieved by stopping the infusion for about an hour, and use of chlorpheniramine injection and acetaminophen oral. Non-serious infections developed in 3 out of 65 patients including 1 with a chest infection (1.5%) and 2 with pharyngitis (3.07%). A study of RTX safety (n=3595) published by Ronald F. at August 2015 stated that RTX has a consistent safety profile over time and multiple courses up to 11 years of observation, the patients in this update did not register increase rate of serious infections [18] . One of our patients developed severe abdominal pain and diarrhea 6hrs after RTX infusion(1.5%), she was admitted to the emergency unit, another patient had generalized itching (1.5%) at the day of infusion.
Van Vollenhoven et al. have recently reported a pooled analysis of the long-term safety of RTX in global clinical trials over 11 years [24] . The initial published data included 3194 patient. Overall, infections (5%) reported in the RTX-treated patients were upper respiratory infections, nasopharyngitis, urinary tract infection, bronchitis, sinusitis, diarrhea, and gastroenteritis, risk of serious infections was stable over time, even with multiple courses of treatment, 2 TB cases, no report on HBV, or HCV reactivation [24] , increased risk of hospitalized infection [25] .
Progressive multifocal leukoencephalitis (PML) is a progressive infection caused by the JC virus, and cases of PML have been reported in RA patients treated with RTX ( 0.001%) [25] RTX was not associated with an increased risk of any malignancy in RA pt. [24] RTX was not available from August 2015November 2015. It is to be noted that during this period the patients did not come for follow up. Also, the prolonged period between two cycles of RTX (6ms) made difficult contact with the patients.
CONCLUSION
• RTX is effective both clinically, functionally and lab. measures. • It is most effective in those patients who are not smokers compared to smokers. • It is more effective in a patient who is seropositive for RF ( there was a great decrease in CDAI in RF-positive group (53.6%) from the RF-negative group (41.2). • RTX is relatively safe with few side effects, tolerable by most patients. The most common side effect is transfusion reaction (26.15%).
